Paclitaxel medac® is:
Mechanism of Action
Natural taxane, prevents depolymerization of cellular microtubules, which results in DNA, RNA, and protein synthesis inhibition
Pharmacokinetics
Protein bound: 89-98%
Vd: 227-688 L/m²
Metabolism: Metabolized by CYP2C8, CYP3A4
Metabolites: 6-alpha-hydroxypaclitaxel (major)
Half-life elimination: 27hr terminal
Excretion: Feces (20%); urine (4%)
Additive: cisplatin (comp at low paxlitaxel conc; incomp at high paclitaxel conc)
Y-site: amphotericin B, amphotericin B cholesteryl sulfate, chlorpromazine, doxorubicin liposomal, hydroxyzine, methylprednisolone sodium succinate, mitoxantrone
Additive: carboplatin, doxorubicin
Y-site (partial list): acyclovir, ampicillin-sulbactam, bleomycin, carboplatin, cisplatin, cytarabine, diphenhydramine, famotidine, furosemide, granisetron, heparin, linezolid, lorazepam, MgSO4, morphine SO4, ondansetron, KCl, propofol, NaHCO3, vancomycin
Further dilution in NS or D5W to a concentration of 0.3-1.2 mg/mL
Standard dilution (IVPB): dose/500-1000 mL D5W or NS
Irritant
Mfr recommends administration over 1-24 hr
Administer taxane derivatives before platinum derivatives (cisplatin, carboplatin) in sequential infusions to limit myelosuppression and to enhance efficacy
Administer corticosteroids, H1-antagonists, H2 antagonists, prior to paclitaxel administration to minimize potential for anaphylaxis
Non-PVC tubing should be used to minimize leaching
Contact of undiluted concentrate with plasticized PVC equipment or devices is not recommended
Administer through IV tubing containing an in-line (0.22 micron) filter
Should be dispensed in either glass or Excel/PAB
injectable solution
Premedicate to prevent hypersensitivity reactions (eg, dexamethasone, diphenhydramine, H2 blockers)
Previously untreated: 175 mg/m² IV over 3 hours q3Weeks (follow with cisplatin), OR
135 mg/m² IV over 24 hours q3Weeks (follow with cisplatin)
Previously treated: Various regimens exist: 135-175 mg/m² IV over 3 hours q3Weeks
Node positive (adjuvant chemotherapy): 175 mg/m² IV over 3 hours q3Weeks 4 times (with doxorubicin-containing regimen)
Metastatic Disease (failure of initial chemotherapy or relapse within 6 months following adjuvant chemotherapy): 175 mg/m² IV over 3 hours q3Weeks
135 mg/m² IV over 24 hours q3Weeks (follow with cisplatin)
135 mg/m² IV over 3 hours q3Weeks; OR
100 mg/m² IV over 3 hours q2Weeks
Investigational: 125 mg/m² IV with gemcitabine
If baseline PMN <1500/m³, do not re-treat until PMN >1500/m³ and platelet count >100,000/m³
If severe neutropenia occurs (PMN <500/m³ for 7 days), reduce subsequent doses by 20%
Renal impairment: No dosage adjustment required
With solid carcinomas and not Kaposi sarcoma
24-hr infusion
3-hr infusion
Off-label: head/neck cancer, small-cell lung cancer, upper GI adenocarcinoma, hormone-refractory prostate cancer, NHL, urothelium transitional cell carcinoma, stage IIB-IV melanoma
>10% |
<1% |
Neutropenia (78-100%) |
Grand mal seizures |
Alopecia (55-96%) |
Cardiac conduction abnormalities |
Anemia (47-96%) |
Frequency Not Defined |
Arthralgia/myalgia (93%) |
Pyrexia |
Diarrhea (90%) |
Dehydration |
Leukopenia (90%) |
Pancytopenia |
Nausea/vomiting (9-88%) |
Congestive heart failure |
Opportunistic infections (76%) |
Left ventricular dysfunction |
Peripheral neuropathy (42-79%) |
Stevens-Johnson syndrome, toxic epidermal necrolysis, and extravasation |
Thrombocytopenia (4-68%) |
Grand mal seizures |
Mucositis (5-45%) |
|
Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions.
Read moreColorectal cancer is a major cause of morbidity and mortality, being one of the most common malignant tumors in the world.
Read moreCancer of the prostate is the most common malignancy in elderly men
Read moreChemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy.
Read moreSome types of cancer may cause bone damage leading to high levels of blood calcium and lesions that cause severe bone pain, bone masses & fractures.
Read more